The CAR toolkit: progress and challenges in CAR T/NK cell R&D and manufacture
Sponsor
Chimeric antigen receptor (CAR) T cell immunotherapy has changed the face of cancer treatment and led to transformative clinical results in some patients. CAR-NK therapies are also gaining traction due to their potential to address some of the ongoing challenges with CAR T cells, such as safety and efficacy.
With numerous clinical trials underway and multiple CAR T cell products now approved, solving the current obstacles when manufacturing CAR-T/NK cell products continues to be a pressing issue for the cellular immunotherapy field. In particular, the ability to evaluate the expression of a CAR following T cell or NK cell transduction is a critical step in the development and production of these cell therapy products.
In this webinar, an expert panel will discuss current challenges, along with the latest progress and innovation, facing CAR T and CAR NK development. In addition, a method for direct staining and detection of specific CARs by flow cytometry will be presented
- Key challenges when developing and manufacturing CAR T/NK cell products
- The importance of the CAR expression evaluation step for CAR T/NK cell R&D and manufacture
- Current methods used for CAR detection and evaluation, along with their advantages and drawbacks
- Fluorescent-labeled proteins that enable direct staining and detection of specific CAR by flow cytometry, providing advantages over antibodies in speed, specificity, and low background staining
SPEAKERS
You might also like
CAR-NK production for clinical applications using BaEV lentivirus and the NK cell engineering platform
Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies
Enhancing CAR-T efficacy for targeting lymphoma and solid tumors
Clinical-scale non-viral gene edited CAR-NK cells for cell therapy
